SUMAVEL DOSEPRO Rx
Generic Name and Formulations:
Sumatriptan (as succinate) 6mg/0.5mL; needle-free delivery system; soln for SC inj.
Indications for SUMAVEL DOSEPRO:
Acute treatment of migraine or cluster headaches.
Limitations Of use:
Confirm diagnosis; reconsider if no response after treatment. Not for prevention of migraine attacks.
≥18yrs: 6mg SC to the abdomen or thigh only. Reevaluate if no response. May repeat after 1 hour; max 12mg in 24hrs.
<18yrs: not recommended.
Ischemic coronary artery disease (CAD) (eg, angina, history of MI, silent ischemia). Coronary artery vasospasm (including Prinzmetal's angina). Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders. History of stroke or TIA. History of hemiplegic or basilar migraine. Peripheral vascular disease. Ischemic bowel disease. Uncontrolled hypertension. Within 24hrs of ergot-type drugs (eg, methysergide, dihydroergotamine) or other 5-HT1 agonists. During or within 2 weeks of an MAO-A inhibitor.
Avoid excessive use. Exclude underlying cardiovascular disease, supervise 1st dose, and consider monitoring ECG in patients with multiple cardiovascular risk factors (eg, increased age, diabetes, hypertension, smokers, obesity, strong family history of CAD). Monitor BP, cardiovascular function in long-term intermittent use. Discontinue if serious arrhythmias or cerebrovascular events occur or if serotonin syndrome is suspected. Peripheral vascular or colonic ischemia following other 5-HT1 agonists. History, or risk of seizures. Severe hepatic impairment: not recommended. Instruct patients on use of DosePro. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Ergotamines, other 5-HT1 agonists, MAO-A inhibitors: see Contraindications. Increased risk of serotonin syndrome with SSRIs, SNRIs, tricyclics, or MAO inhibitors.
Selective 5-HT1B/1D receptor agonist.
Inj site reactions, tingling, dizziness/vertigo, warm/hot or burning sensation, feeling of heaviness or tightness, pressure sensation, flushing, numbness, tight feeling in head, chest or jaw/nasal cavity/sinuses discomfort, drowsiness/sedation, headache; rare: serious cardiac and cerebrovascular events (including fatalities), hypertension, vision loss, hypersensitivity reactions.
Single-dose units (prefilled)—6
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Triiodothyronine in the Treatment of Bipolar Depression
- Suicide Risk After Self-Harm Among Adolescents, Young Adults
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Safety, Efficacy of Deep Brain Stimulation for Alzheimer Disease Examined
- Many Teens Who Use Tobacco Don't Self-Identify as Users